Yazar "Yıldız, Ayşegül" için listeleme
-
Acibenzolar-S-Methyl Inhibits MEK1/2 Signaling in SH-SY5Y Neuroblastoma Cells
Yıldız, Ayşegül (2019)Objective: Targeted cancer therapy using targeted cell proliferation inhibitors has become increasingly more critical. Studies conducted over the last decade have shown that non-steroidal drugs containing salicylic acid ... -
Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma
Tanrıverdi, Özgür; Yıldız, Ayşegül (SAGE Publications Ltd, 2022)Sarcomas probably develop after malignant transformation of embryonic mesenchymal cells and have broad spectrum histopathologically since they can develop from striated skeletal muscle and smooth muscle, fat and fibrous ... -
Effect of the Interaction Between Selenium and Zinc on DNA Repair in Association With Cancer Prevention
Yıldız, Ayşegül; Kaya, Yeşim; Tanrıverdi, Özgür (Korean Soc Cancer Prevention, 2019)Cancer is the most common cause of death worldwide. Annually, more than ten million new cancer cases are diagnosed, and more than six million deaths occur due to cancer. Nonetheless, over 80% of human cancer may be preventable ... -
Extracellular microRNAs: key players to explore the outcomes of in vitro fertilization
Khan, Haroon Latif; Bhatti, Shahzad; Abbas, Sana; Kaloǧlu, Celal; Isa, Ahmed Mostafa; Younas, Hooria; Ziders, Rachel; Yıldız, Ayşegül (BioMed Central Ltd, 2021)Background: MicroRNAs (miRNAs) are small RNA molecules that modulate post-transcriptional gene regulation. They are often used as promising non-invasive biomarkers for the early diagnosis of cancer. However, their roles ... -
p60-katanin: a novel interacting partner for p53
Korulu, Sirin; Yıldız, Ayşegül (Springer, 2020)Katanin, one of the best-characterized microtubule (MT) severing proteins, is composed of two subunits: catalytic p60-katanin, and regulatory p80-katanin. p60-katanin triggers MT reorganization by severing them. MT ... -
The role of Speedy/RINGO in between MAPK and AKT pathways in SH-SY5Y neuroblastoma cells
Tanrıverdi, Özgür; Kaya, Yeşim; Küçükvardar, Seren; Yıldız, Ayşegül (Elsevier, 2020)Deregulated expression of the c-Myc oncogene is an important molecular hallmark of cancer. Previous studies have shown that the murine zinc finger protein ZF5 is a putative transcriptional regulator of c-Myc and can affect ... -
Salicylidene Acylhydrazides attenuate SH-SY5Y neuroblastoma cell survival through mitotic regulator Speedy/RINGO and ERK/ MAPK-PI3K/ AKT pathways
Tanrıverdi, Özgür; Arzıman, Süleyman; Küçükvardar, S.; Yıldız, Ayşegül (Elsevier, 2020)Some lung cancer (LC) patients carry germline truncating mutations in DNA repair or other cancer-related genes, however it is unclear whether these allelic variants play a causative role in LC predisposition, or, alternatively, ... -
Salicylidene acylhydrazides attenuate survival of SH-SY5Y neuroblastoma cells through affecting mitotic regulator Speedy/RINGO and ERK/MAPK-PI3K/AKT signaling
Arzıman, Süleyman; Tanrıverdi, Özgür; Küçükvardar, Seren; Çitil, Neslihan; Yıldız, Ayşegül (Humana Press Inc, 2020)Salicylidene acylhydrazide group synthetic compounds ME0053, ME005 and ME0192 are known for their iron chelating properties and due to these properties they are primarily used for blocking the bacterial type 3 secretory ... -
Speedy/RINGO protein interacts with ERK/MAPK and PI3K/AKT pathways in SH-SY5Y neuroblastoma cells
Kaya, Yeşim; Küçükvardar, Seren; Yıldız, Ayşegül (Springer, 2020)Abnormal activity of ERK/MAPK and PI3K/AKT pathways is one of the most important factors for the development of many cancer types including neuroblastoma cancer. Apart from these two pathways, some cell cycle regulators ... -
Targeting MDM2-p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach
Yıldız, Ayşegül; Ghafoor, Naeem Abdul (PMC, 2023)Cancer remains a major cause of morbidity and mortality worldwide, and while current therapies, such as chemotherapy, immunotherapy, and cell therapy, have been effective in many patients, the development of novel therapeutic ...
